Pfizer's Retacrit (epoetin alfa-epbx- biosimilar) Receives FDA Approval for Anemia
Shots:
- The approval is based on non-inferiority data demonstrating biosimilarity between Retacrit and the reference product- Epogen & Procrit
- In May- 2016 Pfizer and Vifor Pharma collaborated for the commercialization of retacrit in certain therapeutic areas
- Retacrit (epoetin alfa) a biosimilar to Epogen & Procrit- is an erythropoiesis-stimulating agent (ESA) indicated for anemia and reduction in allogeneic red blood cell (RBC) transfusion
Ref: Pfizer | Image: Market Exclusive
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com